IMMP - Immutep Surges 25% on Strong Survival Data for Efti + KEYTRUDA(R) in Head & Neck Cancer

2025-05-05 12:31:21 ET

Immutep (NASDAQ: IMMP ) shares rose 25% following the announcement of compelling new data from its Phase IIb TACTI-003 trial. The combination of the company's immunotherapy candidate, eftilagimod alfa (efti), and Merck's KEYTRUDA(R) (pembrolizumab) delivered a median overall survival of 17.6 months in patients with head and neck cancer with PD-L1 CPS <1--a population with no approved immunotherapy-only options.

These results compare favorably to historical standards of care involving chemotherapy, with median OS ranging from 7.9 to 11.3 months. The regimen was well tolerated with no new safety concerns and builds on earlier data showing high response rates and multiple complete responses.

CEO Marc Voigt called the results a "strong survival benefit" and highlighted the potential for this chemo-free combination to deliver more durable, clinically meaningful outcomes for patients who currently have limited treatment options.

Immutep has requested a meeting with the FDA to discuss potential paths to approval in this high unmet-need population. Efti currently holds Fast Track designation in first-line HNSCC.

More updates are expected later this year as the company continues follow-up and data analysis.

About Immutep

Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders.

The post Immutep Surges 25% on Strong Survival Data for Efti + KEYTRUDA(R) in Head & Neck Cancer appeared first on PRISM MarketView .

COMTEX_465237893/2927/2025-05-05T11:31:21